Cardiac Safety Outcomes in Delandistrogene Moxeparvovec Clinical Trials for Duchenne Muscular Dystrophy with Up to 5 Years of Follow-up.

Cardiac Safety Outcomes in Delandistrogene Moxeparvovec Clinical Trials for Duchenne Muscular Dystrophy with Up to 5 Years of Follow-up.

Managing the Heart in Gene Therapy for DMD

Can a therapy designed to fix muscles inadvertently damage the heart? Researchers studying Duchenne muscular dystrophy (DMD) face this exact tension. New gene therapies aim to restore muscle function. However, there is a lingering concern that the body's immune response might trigger inflammation in the heart muscle.

A new study analyzes data from up to five years of follow-up. It examines the cardiac safety of delandistrogene moxeparvovec, a gene transfer therapy for DMD. The researchers report that some cases of heart inflammation occurred. These cases were manageable and did not lead to persistent cardiac injury in the studied population.

Assessing the Risk of Myocardial Inflammation

The core concern is differentiating between the natural progression of DMD and potential side effects from the therapy. In DMD, the heart muscle eventually weakens. This often leads to cardiorespiratory failure, which is the leading cause of death for these patients. Because the therapy uses an adeno-associated virus (AAV; a small virus used as a delivery vehicle) to deliver genes, scientists must monitor the heart. They must ensure the immune system does not attack the heart during delivery.

Think of the AAV vector as a specialized delivery truck. It carries a vital blueprint to a construction site. The risk is that the body's security system might mistake the truck for an intruder. This could cause "collateral damage," or inflammation, at the site meant for repair. The authors sought to determine if this damage leads to long-term structural changes in the heart.

The Mechanics of Duchenne Muscular Dystrophy

To understand the stakes, one must understand the pathology of DMD. It is a rare genetic disorder. It is caused by mutations in the DMD gene. These mutations prevent the production of dystrophin. Dystrophin is a protein that acts like a shock absorber for muscle cells. Without it, mechanical stress causes cell membranes to tear. This leads to progressive muscle wasting.

Delandistrogene moxeparvovec is a recombinant AAV-based therapy. It aims to address this by delivering a functional "micro-dystrophin" gene. This gene is driven by the MHCK7 promoter (a biological "switch" that turns genes on). This switch is engineered to be highly active in both skeletal and cardiac muscle. Because the therapy targets the heart to prevent cardiomyopathy (disease of the heart muscle), monitoring cardiac health is a central requirement.

The researchers monitored several key metrics: * Troponin I: A protein released into the blood when heart muscle cells are damaged. It serves as a sensitive "smoke detector" for cardiac injury. * LVEF (Left Ventricular Ejection Fraction): A percentage representing how much blood the left ventricle pumps out with each contraction. It measures how effectively the heart functions. * Echocardiography (ECHO) and Cardiac MRI (cMRI): Ultrasound and magnetic resonance tools used to visualize the heart's structure and movement.

Tracking Long-Term Cardiac Stability

The authors performed a pooled analysis of 218 patients across four clinical trials. By aggregating data, they could observe trends over a much longer window.

The study found that 24% of the 216 treated patients experienced cardiac treatment-emergent adverse events (TEAEs; side effects appearing after treatment). However, the nature of these events is critical. The most common issue was increased troponin I levels. This occurred in 12% of patients. As shown in, many of these fluctuations were asymptomatic. They appeared consistent with the natural history of DMD. In DMD, troponin levels can rise and fall due to the disease itself.

Regarding severe inflammation, the paper reports only three total cases of myocarditis (inflammation of the heart muscle). Of these, two were deemed treatment-related by physicians. Crucially, both cases resolved within three weeks.

Pump function remained largely stable. The researchers report that LVEF remained stable over several years in the studied cohorts. In the EMBARK cMRI substudy, researchers used advanced imaging to look at heart volume and mass. They found no relevant differences in heart function between treated patients and those who received a placebo . Similarly, ECHO data across the wider sample showed stable LVEF values over time [Figure 3c].

Defining the Safety Profile

This analysis moves from theoretical concerns to a documented reality. The study suggests the cardiac safety profile is manageable for younger, predominantly ambulatory (able to walk) patients.

Clinicians should not view every spike in troponin I as a sign of therapy failure. Instead, these markers should be interpreted alongside clinical symptoms and imaging. The finding that treatment-related myocarditis resolved quickly with standard care provides a clear clinical pathway. This helps manage the known risks.

Identifying the Limits of the Data

The authors note that these findings have specific boundaries. First, the study population was skewed toward younger patients. Ninety percent were under age 8. The study also excluded anyone with an LVEF below 40%. Cardiac dysfunction in DMD typically becomes more severe in patients aged 10 or older. Therefore, the results may not apply to older or more advanced stages of the disease.

The researchers also highlight technical gaps in current monitoring. The EMBARK cMRI substudy did not use gadolinium enhancement (a contrast agent used to highlight tissue details). Without this, the authors admit that "subclinical fibrosis" (tiny areas of permanent scarring) cannot be entirely ruled out. Future studies, such as the ongoing ENVISION trial, will be necessary. They must characterize safety in older and non-ambulatory populations.

Figures from the paper